ME1 great news and more to come --
12 October 2023
Wholly-owned subsidiary Halucenex Life Sciences Inc. achieves
remission in 80% of first five patients in Phase II clinical trial
Highlights:
• Encouraging early results from Phase II clinical trial to test the efficacy of psilocybin on treatmentresistant Post Traumatic Stress Disorder (PTSD)
• Five patients have undergone testing to date with 80% of participants experiencing total remission
from PTSD symptoms following two doses of Halucenex’s 100%-owned synthetic psilocybin aqueous
solution Lucenex
• Additional results from first five patients include:
o 50% reduction in anxiety scores from baseline to day 44 of treatment
o 57% reduction in depression scores from baseline to day 44 of treatment
• Initial results are positive given conventional treatments for anxiety and depression are only around
20-30% effective
- Forums
- ASX - Day Trading
- Morning Trading October 12
Morning Trading October 12, page-53
-
- There are more pages in this discussion • 188 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)